<DOC>
	<DOC>NCT01976858</DOC>
	<brief_summary>Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG). This study aims to evaluate the PK, PD and safety by 8-week continuous treatment of PEX168.</brief_summary>
	<brief_title>A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. aged 2065 years old, male or female, diagnosis of type 2 diabetes according to the 1999 WHO criteria more than 3 months. 2. HbA1C 7.010.0% and fasting plasma glucose 7.010.0 mmol/L after treatment of diet, exercise or a single oral hypoglycemic agents (metformin , glimepiride or pioglitazone). 3. unused insulin within 3 months prior to the enrollment. 4. Body mass index within the range from 19 to 35, and body weight does not changes exceeding 10% in the past 3 months. 5. Normol liver, kidney, heart function. 6. Willing to use physical means of contraception during the trial stage. 7. voluntarily to participate in the study. 1. 1 diabetes. 2. used GLP1, GLP1 analogs or DPP4 inhibitors in the past 3 months. 3. have diabetic ketoacidosis , diabetic hyperosmolar nonketotic coma patients with a history 4. There is a history of severe hypoglycemia : such as low blood sugar cause drowsiness , unconsciousness , nonsense , and even coma. 5. with severe diabetes complications ( renal , retinal , nerve , vascular disease). 6. has acute and chronic pancreatitis history ; 7. heart failure , unstable angina , severe arrhythmia, patients with a history of myocardial infarction ; 8. There is a history of hypertension and blood pressure is not well controlled : SBP&gt; 160mmHg and / or DBP&gt; 95mmHg persons ; 9. severe chronic gastrointestinal disease ( active ulcer nearly six months ) or have been affecting drug absorption in patients treated ; 10. There are obvious blood system diseases ; 11. There are other endocrine system diseases , such as hyperthyroidism , etc. ; 12. with severe trauma or surgery , severe infection ; 13. have mental illness , drug or other substance abuse or alcoholism ( drinking at least 2 times per week , more than 100g each drink ) ; 14. used any drugs that may affect the study , within 3 months before treatment as the subjects participated in any clinical trials ; 15. within the past six months more than 400ml of blood loss (including blood , trauma or other reasons ) ; 16. were receiving steroids or are receiving cancer treatment ; 17. has been prepared during pregnancy or pregnancy test in female patients ; 18. hepatitis B HBeAg , hepatitis C antibody positive , HIV antibody positive , syphilis antibody positive . 19. skin test positive of PEX168; 20. The researchers considered any factors that the subject should not participate in this trial.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>PEX168, diabetes, phase I</keyword>
</DOC>